Global Perspectives: Current and Future Management of Breast Cancer

Expert perspectives and strategic insights on the latest therapeutic developments in breast cancer

November 7 and 8, 2023
Nadia Harbeck


Nadia Harbeck, MD, PhD

Ludwig-Maximilian University of Munich, Germany


Joyce A. O’Shaughnessy, MD

Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA

Faculty Members

Mark Pegram, MD
Stanford University School of Medicine, CA, USA

Melinda L. Telli, MD
Stanford University School of Medicine, CA, USA

Komal Jhaveri, MD, FACP
Memorial Sloan Kettering Cancer Center, New York, NY, USA

Reshma L. Mahtani, DO
Miami Cancer Institute, Baptist Health South Florida, USA

Peter Schmid, MD, PhD
St Bartholomew’s Hospital, London, UK

Joseph Gligorov, MD, PhD
Tenon Hospital (AP-HP), Paris, France

Valentina Guarneri, MD, PhD
University of Padua, Italy

Javier Cortés, MD, PhD
International Breast Cancer Center, Barcelona, Spain

Sample Report

Start discovering the insights

View Report


  • Current and Emerging Biomarkers and Testing Methodologies in BC
  • Therapeutic Horizons in HR+ Advanced BC
  • Clinical Implications of HER2-Low BC
  • Maximizing Potential Targeting of HER2 in HER2+ mBC
  • Therapeutic Horizons in HR+ Early BC
  • The Changing Landscape of HER2+ Early BC
  • Standard and Emerging Strategies for High-Risk, Early-Stage TNBC
  • Current and Investigational Approaches in Metastatic TNBC

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.